Needle adapters for intradermal administration of fractional dose of inactivated poliovirus vaccine: Evaluation of immunogenicity and programmatic feasibility in Pakistan

Ali Faisal Saleem, Ondrej Mach, Mohammad T Yousafzai, Asia Khan, William C Weldon, M Steven Oberste, Roland W Sutter, Anita K M Zaidi, Ali Faisal Saleem, Ondrej Mach, Mohammad T Yousafzai, Asia Khan, William C Weldon, M Steven Oberste, Roland W Sutter, Anita K M Zaidi

Abstract

Administration of 1/5th dose of Inactivated poliovirus vaccine intradermally (fIPV) provides similar immune response as full-dose intramuscular IPV, however, fIPV administration with BCG needle and syringe (BCG NS) is technically difficult. We compared immune response after one fIPV dose administered with BCG NS to administration with intradermal devices, referred to as Device A and B; and assessed feasibility of conducting a door-to-door vaccination campaign with fIPV. In Phase I, 452 children 6-12months old from Karachi were randomized to receive one fIPV dose either with BCG NS, Device A or Device B in a health facility. Immune response was defined as seroconversion or fourfold rise in polio neutralizing antibody titer 28days after fIPV among children whose baseline titer ≤362. In Phase II, fIPV was administered during one-day door-to-door campaign to assess programmatic feasibility by evaluating vaccinators' experience. For all three poliovirus (PV) serotypes, the immune response after BCG NS and Device A was similar, however it was lower with Device B (34/44 (77%), 31/45 (69%), 16/30 (53%) respectively for PV1; 53/78 (68%), 61/83 (74%), 42/80 (53%) for PV2; and; 58/76 (76%), 56/80 (70%), 43/77 (56%) for PV3; p<0.05 for all three serotypes). Vaccinators reported problems filling Device B in both Phases; no other operational challenges were reported during Phase II. Use of fIPV offers a dose-saving alternative to full-dose IPV.

Keywords: Immune response; Inactivated polio vaccine; Intradermal injections; fractional dose IPV.

Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.

Figures

Fig. 1
Fig. 1
Immune response (seroconversion or boosting of antibody titer) after one fIPV dose among children who completed all study visits and had baseline titer ≤362 [error bars: 95%CI]. * – Significant difference between Device B and BCG NS study arms (p 

Fig. 2

Indicators of successful injection (from…

Fig. 2

Indicators of successful injection (from Phase I) [error bars: 95%CI]. * – Significant…

Fig. 2
Indicators of successful injection (from Phase I) [error bars: 95%CI]. * – Significant difference between Device B and BCG NS study arms (p 
Similar articles
References
    1. Cases of wild poliovirus by country and year. Available at: http://www.polioeradication.org/Dataandmonitoring/Poliothisweek/Wildpoli... [accessed 12/20/2016].
    1. Sutter R.W., Platt L., Mach O., Jafari H., Aylward R.B. The new polio eradication end game: rationale and supporting evidence. J Infect Dis. 2014;210(Suppl 1):S434–S438. - PubMed
    1. Centers for Disease C, Prevention Apparent global interruption of wild poliovirus type 2 transmission. MMWR Morb Mortal Wkly Rep. 2001;50:222–224. - PubMed
    1. GPEI. Global switch in oral polio vaccines. Available at: http://maps.who.int/OPV_switch/ [accessed 07/06/2016].
    1. WHO. Outbreak response: a package of guidelines and materials. Available at: http://www.polioeradication.org/Resourcelibrary/Resourcesforpolioeradica....
Show all 23 references
Publication types
MeSH terms
Substances
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM
Fig. 2
Fig. 2
Indicators of successful injection (from Phase I) [error bars: 95%CI]. * – Significant difference between Device B and BCG NS study arms (p 

References

    1. Cases of wild poliovirus by country and year. Available at: [accessed 12/20/2016].
    1. Sutter R.W., Platt L., Mach O., Jafari H., Aylward R.B. The new polio eradication end game: rationale and supporting evidence. J Infect Dis. 2014;210(Suppl 1):S434–S438.
    1. Centers for Disease C, Prevention Apparent global interruption of wild poliovirus type 2 transmission. MMWR Morb Mortal Wkly Rep. 2001;50:222–224.
    1. GPEI. Global switch in oral polio vaccines. Available at: [accessed 07/06/2016].
    1. WHO. Outbreak response: a package of guidelines and materials. Available at: .
    1. SAGE. SAGE discussion and statement in relation with the IPV supply situation. Available at: [accessed 23/06/2016].
    1. Resik S., Tejeda A., Mach O. Needle-free jet injector intradermal delivery of fractional dose inactivated poliovirus vaccine: association between injection quality and immunogenicity. Vaccine. 2015;33:5873–5877.
    1. Mohammed A.J., AlAwaidy S., Bawikar S. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med. 2010;362:2351–2359.
    1. Nirmal S., Cherian T., Samuel B.U., Rajasingh J., Raghupathy P., John T.J. Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine. Vaccine. 1998;16:928–931.
    1. Resik S., Tejeda A., Mach O. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine. 2015;33:307–313.
    1. Estivariz C.F., Jafari H., Sutter R.W. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6–9 months in Moradabad, India: a community-based, randomised controlled trial. Lancet Infect Dis. 2012;12:128–135.
    1. Soonawala D., Verdijk P., Wijmenga-Monsuur A.J. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine. 2013;31:3688–3694.
    1. Nelson K.S., Janssen J.M., Troy S.B., Maldonado Y. Intradermal fractional dose inactivated polio vaccine: a review of the literature. Vaccine. 2012;30:121–125.
    1. Resik S., Tejeda A., Lago P.M. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis. 2010;201:1344–1352.
    1. Resik S., Tejeda A., Sutter R.W. Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med. 2013;368:416–424.
    1. Polio vaccines: WHO position paper. Wkly Epidemiol Rec. 2016;91(March):145–168.
    1. Sheikh M.A., Makokha F., Hussein A.M. Combined use of inactivated and oral poliovirus vaccines in refugee camps and surrounding communities – Kenya, December 2013. MMWR Morb Mortal Wkly Rep. 2014;63:237–241.
    1. WestPharma. Introducing the west intradermal adapter. Available at: [accessed 08/06/2016].
    1. Syringe S. Star ID: intradermal delivery made easy. Available at: .
    1. Sutter R.W., Pallansch M.A., Sawyer L.A., Cochi S.L., Hadler S.C. Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: poliovirus vaccination. Ann N Y Acad Sci. 1995;754:289–299.
    1. WHO Expanded Programme on Immunization. World Health Organization. Division of communicable diseases. Manual for the virological investigation of poliomyelitis. Geneva: World Health Organization; 1990.
    1. Fiore L., Plebani A., Buttinelli G. Search for poliovirus long-term excretors among patients affected by agammaglobulinemia. Clin Immunol. 2004;111:98–102.
    1. Weldon W.C., Oberste M.S., Pallansch M.A. Standardized methods for detection of poliovirus antibodies. Methods Mol Biol. 2016;1387:145–176.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe